Alerts will be sent to your verified email
Verify Email
HIKAL
|
Hikal
|
Suven Life Sciences
|
Piramal Pharma
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
API Sector
|
|||
|
Total reactor capacity
|
145.0 kL | n/a | n/a |
|
Pharmaceutical Sector
|
|||
|
R&D as a % of Total Sales
|
4.01 % | 490.0 % | 0.71 % |
|
Financials
|
|||
|
5 yr Average ROE
|
10.48 % | -65.97 % | 4.5 % |
|
5yr average Equity Multiplier
|
2.17 | 1.69 | 1.97 |
|
5yr Average Asset Turnover Ratio
|
0.81 | 0.05 | 0.53 |
|
5yr Avg Net Profit Margin
|
5.87 % | -798.21 % | 4.14 % |
|
Price to Book
|
4.27 | 14.82 | 3.75 |
|
P/E
|
68.95 | 0.0 | 762.22 |
|
5yr Avg Cash Conversion Cycle
|
33.87 Days | 54.79 Days | -17.8 Days |
|
Inventory Days
|
64.21 Days | 5.7 Days | 68.38 Days |
|
Days Receivable
|
101.46 Days | 32.67 Days | 76.2 Days |
|
Days Payable
|
96.57 Days | 7.08 Days | 156.5 Days |
|
5yr Average Interest Coverage Ratio
|
4.8 | -218.98 | 3.08 |
|
5yr Avg ROCE
|
13.73 % | -67.21 % | 6.74 % |
|
5yr Avg Operating Profit Margin
|
16.42 % | -890.08 % | 15.07 % |
|
5 yr average Debt to Equity
|
0.68 | 0.01 | 0.63 |
|
5yr CAGR Net Profit
|
-3.79 % | 2.21 % | -53.67 % |
|
5yr Average Return on Assets
|
4.82 % | -37.69 % | 2.39 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
68.85 % | 70.27 % | 34.95 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
0.08 % | 5.29 % | 0.16 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
2.17 % | 0.0 | 12.19 % |
|
Hikal
|
Suven Life Sciences
|
Piramal Pharma
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
|
Operating Profit Break-Up
|
Operating Profit Break-Up
|
-
|
-
|
|
Asset Break-Up
|
Asset Break-Up
|
Asset Break-Up
|
-
|